{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:13:37Z","timestamp":1771470817068,"version":"3.50.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The JAVELIN Bladder 100 trial established avelumab maintenance as standard care for advanced urothelial carcinoma (UC). However, Asian (n\u00a0=\u00a0147) and Japanese (n\u00a0=\u00a073) subgroups showed non-significant results with wide confidence intervals, as expected given limited sample sizes. We sought to provide complementary insights using Bayesian methods that quantify probability of treatment benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed Bayesian reanalysis using published data from JAVELIN Bladder 100. The global trial data (n\u00a0=\u00a0700; HR\u00a0=\u00a00.76, 95% CI: 0.63\u20130.91) informed prior distributions across four scenarios: neutral prior (no borrowing), conservative borrowing (prior SD\u00a0=\u00a02\u00a0\u00d7\u00a0Standard Error [SE]), moderate borrowing (prior SD\u00a0=\u00a01.5\u00a0\u00d7\u00a0SE), and strong borrowing (prior SD\u00a0=\u00a0SE). Posterior distributions were derived using normal-normal conjugate updating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the Asian cohort, posterior mean hazard ratios ranged from 0.754\u20130.758 across borrowing scenarios, with probability of benefit P(HR\u00a0&amp;lt;\u00a01) ranging from 85.5% (neutral) to 99.9% (strong). The Japanese cohort showed posterior mean HRs of 0.763\u20130.828, with P(HR\u00a0&amp;lt;\u00a01) ranging from 71.9% (neutral) to 99.9% (strong). Under moderate borrowing, both cohorts achieved credible intervals excluding 1.0 (Asian: 0.591\u20130.966; Japanese: 0.594\u20130.990). Probability of clinically meaningful benefit P(HR\u00a0&amp;lt;\u00a00.8) reached 67.5% in Asian and 62.7% in Japanese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While statistical limitations exist regarding the non-independence of data sources and dominance of global information, the high probabilities of benefit across all analytical scenarios support the use of avelumab in these populations. These findings illustrate both the utility and limitations of Bayesian methods in interpreting underpowered regional subgroups, supporting equitable access to effective cancer therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf166","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:01:39Z","timestamp":1760097699000},"page":"216-220","source":"Crossref","is-referenced-by-count":1,"title":["Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trial"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-8446","authenticated-orcid":false,"given":"Shugo","family":"Yajima","sequence":"first","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East , Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East , Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-3345","authenticated-orcid":false,"given":"Motohiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo University Hospital , Mizonokuchi, Kawasaki ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East , Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026021308523055300_ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026021308523055300_ref2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021308523055300_ref3","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021308523055300_ref4","doi-asserted-by":"publisher","first-page":"256.e17","DOI":"10.1016\/j.urolonc.2023.02.002","article-title":"Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN bladder 100 Asian subgroup analysis","volume":"41","author":"Lee","year":"2023","journal-title":"Urol Oncol"},{"key":"2026021308523055300_ref5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10147-021-02067-8","article-title":"Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN bladder 100 Japanese subgroup analysis","volume":"27","author":"Tomita","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2026021308523055300_ref6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.ijrobp.2021.12.011","article-title":"Understanding the differences between Bayesian and frequentist statistics","volume":"112","author":"Fornacon-Wood","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026021308523055300_ref7","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"Spiegelhalter","year":"2004"},{"key":"2026021308523055300_ref8","doi-asserted-by":"crossref","DOI":"10.1201\/EBK1439825488","volume-title":"Bayesian adaptive methods for clinical trials","author":"Berry","year":"2010"},{"key":"2026021308523055300_ref9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm Stat"},{"key":"2026021308523055300_ref10","doi-asserted-by":"publisher","first-page":"1781333","DOI":"10.1080\/2162402X.2020.1781333","article-title":"A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy","volume":"9","author":"Peng","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026021308523055300_ref11","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry E5 \u2013 Ethnic Factors in the Acceptability of Foreign Clinical Data Questions and Answers","year":"2006"},{"key":"2026021308523055300_ref12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/iju.15473","article-title":"J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan","volume":"31","author":"Kikuchi","year":"2024","journal-title":"Int J Urol"},{"key":"2026021308523055300_ref13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jjco\/hyac186","article-title":"Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study","volume":"53","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/216\/65023765\/hyaf166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/216\/65023765\/hyaf166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:52:38Z","timestamp":1770990758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/2\/216\/8305698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf166","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,29]]}}}